EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Neutralizing antibody response to SARS‐CoV‐2 bivalent mRNA vaccine in SIV‐infected rhesus macaques: Enhanced immunity to XBB subvariants by two‐dose vaccination

Julia N Faraone, Xiaolwei Wang, Panke Qu, Yi-Min Zheng, Eunice Vincent, Huanbin Xu, Shan-Lu Liu

Journal of Medical Virology · 2024

DOI: 10.1002/jmv.29520 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Julia N Faraone und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Retrovirus Research, The Ohio State University, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: mRNA Vaccines, COVID-19. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NICHD NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The evolution of SARS‐CoV‐2 paired with immune imprinting by prototype messenger RNA (mRNA) vaccine has challenged the current vaccination efficacy against newly emerged Omicron subvariants. In our study, we investigated a cohort of macaques infected by SIV and vaccinated with two doses of bivalent Pfizer mRNA vaccine containing wildtype and BA.5 spikes. Using a pseudotyped lentivirus neutralization assay, we determined neutralizing antibody (nAb) titers against new XBB variants, i.e., XBB.1.5, XBB.1.16, and XBB.2.3, alongside D614G and BA.4/5. We found that compared to humans vaccinated with three doses of monovalent mRNA vaccine plus a bivalent booster, the monkeys vaccinated with two doses of bivalent mRNA vaccines exhibited relatively increased titers against XBB subvariants. Of note, SIV‐positive dam macaques had reduced nAb titers relative to SIV‐negative dams. Additionally, SIV positive dams that received antiretroviral therapy had lower nAb titers than untreated dams. Our study underscores the importance of reformulating the COVID‐19 vaccine to better protect against newly emerged XBB subvariants as well as the need for further investigation of vaccine efficacy in individuals living with HIV‐1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

mRNA VaccinesCOVID-19HumansAnimalsMacaca mulattaVaccines, CombinedSARS-CoV-2COVID-19 VaccinesVaccinationAntibodies, NeutralizingRNA, MessengerAntibodies, Viral

Stichwörter der Autor:innen

SARS‐CoV‐2SIVmRNA vaccinationneutralizing antibodyrhesus macaque

Substanzen

Vaccines, CombinedmRNA VaccinesCOVID-19 VaccinesAntibodies, NeutralizingRNA, MessengerAntibodies, Viral

Autor:innen und Institutionen

  • Center for Retrovirus Research, The Ohio State University, Columbus, Ohio, USA.
  • Department of Veterinary Biosciences, The Ohio State University, Columbus, Ohio, USA.
  • Molecular, Cellular, and Developmental Biology Program, The Ohio State University, Columbus, Ohio, USA.
  • Tulane National Primate Research Center, Tulane University School of Medicine, Tulane University, Covington, Louisiana, USA.
  • Viruses and Emerging Pathogens Program, Infectious Diseases Institute, The Ohio State University, Columbus, Ohio, USA.
  • Department of Microbial Infection and Immunity, The Ohio State University, Columbus, Ohio, USA.

Förderung

  • NCI NIH HHS
  • NICHD NIH HHS
  • NIAID NIH HHS
  • NIH HHS
  • NIMH NIH HHS
  • National Science Foundation
  • National Cancer Institute

Zitieren

APA

Faraone, J. N., Wang, X., Qu, P., Zheng, Y. M., Vincent, E., Xu, H., & Liu, S. L. (2024). Neutralizing antibody response to SARS‐CoV‐2 bivalent mRNA vaccine in SIV‐infected rhesus macaques: Enhanced immunity to XBB subvariants by two‐dose vaccination. Journal of Medical Virology. https://doi.org/10.1002/jmv.29520

Vancouver

Faraone JN, Wang X, Qu P, Zheng YM, Vincent E, Xu H, et al. Neutralizing antibody response to SARS‐CoV‐2 bivalent mRNA vaccine in SIV‐infected rhesus macaques: Enhanced immunity to XBB subvariants by two‐dose vaccination. Journal of Medical Virology. 2024. doi:10.1002/jmv.29520

BibTeX
@article{Faraone2024,
  author = {Faraone, Julia N and Wang, Xiaolwei and Qu, Panke and Zheng, Yi-Min and Vincent, Eunice and Xu, Huanbin and Liu, Shan-Lu},
  title = {Neutralizing antibody response to SARS‐CoV‐2 bivalent mRNA vaccine in SIV‐infected rhesus macaques: Enhanced immunity to XBB subvariants by two‐dose vaccination},
  journal = {Journal of Medical Virology},
  year = {2024},
  doi = {10.1002/jmv.29520}
}
Kostenlos starten →